Alteogen

Update in progress

196170.KQ (KOSDAQ)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ALTEOGEN Inc. is a biopharma company developing long-acting biobetters, antibody-drug conjugates, and antibody biosimilars. Its pipeline includes ALT-P1 (long-acting growth hormone, Phase IIa), ALT-Q2 (long-acting factor VII for hemophilia), ALT-P7 (targeted cancer drug, Phase I), ALT-Q5 (ADC for ovarian cancer), and ALT-LS2 (subcutaneous trastuzumab). It collaborates with Kissei (ALT-L9 Eylea biosimilar), Cristalia (ALT-L2 trastuzumab biosimilar), and Biogen (SC biologics ALT-B4). Founded 2008 in Daejeon, Korea.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive